In this large trial of patients with acute stroke (ischemic or hemorrhagic) and systolic blood pressure >140 mmHg, they were randomized to candesartan or placebo for 7 days. At 6 months, there was no difference in recurrent vascular events, but the candesartan group had significantly worse functional outcomes. Blood pressure lowering with candesartan during acute stroke is not beneficial (abstract)
Share This Post
Categories
Related Posts
In this large multicenter trial, patients with minor stroke or TIA were randomized to clopidogrel+ASA or ASA alone; 90-day stroke occurred in 8% vs 12% respectively, and rates of hemorrhage or hemorrhagic stroke were the same (abstract).
These guidelines provide an evidence based for the use of periprocedural antithrombotics in patients with cerebrovascular disease. They recommend continuing ASA-warfarin for dental procedures, and most other minor procedures. There is little evidence to support the use of procedural bridging with heparin, and it does increase the risk of bleeding. Cessation of therapy for 7 […]
A large analysis from a stroke registry found better outcomes with earlier thrombolytics for acute ischemic stroke; every 15 minutes earlier was associated with an odds ratio of 0.96 for in-hospital death or intracranial hemorrhage, and an odds ratio of 1.03 for being discharged home and 1.04 for walking independently at discharge (abstract).
Leave A Comment